Plain-English translation of NCT07560618 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing roflumilast 0.15% cream, a new topical treatment designed to reduce itching from atopic dermatitis (eczema). Researchers want to understand how the medication affects itch over time and what people experience when using it. The study will track your symptoms and itch levels for 4 weeks as you apply this cream daily.
Itching is one of the most bothersome symptoms of atopic dermatitis, often making it hard for people to sleep and affecting quality of life. This trial is exploring whether this medication can provide meaningful relief from that persistent, uncomfortable itch.
You likely qualify if…
You likely don't qualify if…
You would apply the cream to affected areas of your skin once daily for 4 weeks. Each day, you would use a smartphone app to answer a brief survey about your itching levels at approximately the same time. You would attend baseline and follow-up visits where the study team evaluates your skin and measures changes in your symptoms.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States